Table 2.
Dependent variable: AEFI (Yes) | |||||
---|---|---|---|---|---|
OR (95% CI) | p-value | aOR* (95% CI) | p-value | ||
Sex | Men Women |
1 2.17 (1.94-2.43) |
0.000 | 1 2.24 (2.00- 2.50) |
<0.001 |
Age | As the unit increases | 0.98 (0.97-0.98) | 0.000 | 0.98 (0.97-0.98)^ | <0.001 |
Age | 0-19 20-39 40-59 ≥ 60 |
1 0.83 (0.68- 1.01) 0.46 (0.38-0.56) 0.42 (0.34-0.51) |
0.060 0.000 0.000 |
1 0.85 (0.71-1.03)^ 0.47 (0.39-0.57)^ 0.40 (0.33-0.50)^ |
0.104 0.000 0.000 |
Type of vulnerability categories | Other Age ≥ 60 Previous pathology |
1 0.65 (0.57-0.75) 1.26 (1.05-1.51) |
0.000 0.011 |
1 0.62 (0.54-0.71)^ 1.47 (1.22-1.76) |
<0.001 <0.001 |
Type of vaccine | Pfizer (Comirnaty) Astrazeneca (Vaxzevria) Moderna (Spikevax) Janssen (Johnson & Johnson) |
1 0.75 (0.59-0.95) 1.32 (1.06-1.65) 1.48 (1.12-1.95) |
0.018 0.014 0.006 |
1 1.19 (0.92-1.53) 1.35 (1.09-1.69) 2.06 (1.52-2.67) |
0.176 0.007 <0.001 |
Dosage | First dose Second dose |
1 0.46 (0.38-0.55) |
0.000 | 1 0.55 (0.46-0.66) |
<0.001 |
* The model was adjusted for sex and age
^ Only adjusted for sex